These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23165366)

  • 1. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials.
    Fusar-Poli P; Kempton MJ; Rosenheck RA
    Int Clin Psychopharmacol; 2013 Mar; 28(2):57-66. PubMed ID: 23165366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Aug; 63(8):1237-48. PubMed ID: 19624791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies.
    Fusar-Poli P; Berger G
    J Clin Psychopharmacol; 2012 Apr; 32(2):179-85. PubMed ID: 22367656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
    Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
    J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
    Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
    J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
    Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
    Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
    Citrome L
    Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuity of care among patients newly initiated on second-generation oral or long-acting injectable antipsychotics during a schizophrenia-related inpatient stay.
    Patel C; Pilon D; Morrison L; Holiday C; Lafeuille MH; Lefebvre P; Benson C
    Curr Med Res Opin; 2023 Aug; 39(8):1157-1166. PubMed ID: 37461233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting injectable antipsychotics in early psychosis: a literature review.
    Emsley R; Chiliza B; Asmal L; Mashile M; Fusar-Poli P
    Early Interv Psychiatry; 2013 Aug; 7(3):247-54. PubMed ID: 23342964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials.
    Kishi T; Oya K; Iwata N
    Psychiatry Res; 2016 Dec; 246():750-755. PubMed ID: 27863801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-generation antipsychotic long-acting injections in bipolar disorder: Systematic review and meta-analysis.
    Prajapati AR; Wilson J; Song F; Maidment I
    Bipolar Disord; 2018 Dec; 20(8):687-696. PubMed ID: 30417552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
    Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
    Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amantadine for Antipsychotic-Related Weight Gain: Meta-Analysis of Randomized Placebo-Controlled Trials.
    Zheng W; Wang S; Ungvari GS; Ng CH; Yang XH; Gu YH; Li M; Xiang YQ; Xiang YT
    J Clin Psychopharmacol; 2017 Jun; 37(3):341-346. PubMed ID: 28383359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.